scholarly article | Q13442814 |
P356 | DOI | 10.5213/INJ.1732646.323 |
P8608 | Fatcat ID | release_mxc6wfwlibf3pgd6cyijzhowku |
P932 | PMC publication ID | 5380821 |
P698 | PubMed publication ID | 28361515 |
P50 | author | Yuanshan Cui | Q89088688 |
Zhenli Gao | Q89088690 | ||
Hejia Yuan | Q96037692 | ||
Jitao Wu | Q96037694 | ||
Peng Peng | Q96037696 | ||
Xujie Sun | Q96037699 | ||
P2093 | author name string | Jitao Wu | |
Zhenli Gao | |||
Peng Peng | |||
Yuanshan Cui | |||
Hejia Yuan | |||
Xujie Sun | |||
P2860 | cites work | Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. | Q53155089 |
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. | Q53317478 | ||
Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results | Q74206910 | ||
Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study | Q80973713 | ||
Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study | Q81833229 | ||
Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis | Q83445672 | ||
Botulinum Toxin-A Injections Into Neurogenic Overactive Bladder—To Include or Exclude the Trigone? A Prospective, Randomized, Controlled Trial | Q85205665 | ||
OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review | Q26826756 | ||
Meta-analysis in clinical trials | Q27860779 | ||
Botulinum neurotoxin serotype A suppresses neurotransmitter release from afferent as well as efferent nerves in the urinary bladder. | Q33915263 | ||
The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society | Q35057109 | ||
Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins | Q35187504 | ||
Adverse events after botulinum A toxin injection for neurogenic voiding disorders | Q36059392 | ||
Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. | Q36373708 | ||
Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? | Q36574048 | ||
Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis | Q36804908 | ||
OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology | Q37299990 | ||
EAU guidelines on neurogenic lower urinary tract dysfunction | Q37464377 | ||
OnabotulinumtoxinA improves quality of life in patients with neurogenic detrusor overactivity | Q37536741 | ||
Controversy over the pharmacological treatments of storage symptoms in spinal cord injury patients: a literature overview | Q37951376 | ||
Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy | Q39825759 | ||
Vesico-ureteric reflux in adult patients with spinal injury. | Q41513979 | ||
Urinary tract infection in patients with neurogenic bladder dysfunction | Q43555532 | ||
An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity | Q44539406 | ||
New therapeutic options for refractory neurogenic detrusor overactivity | Q44934769 | ||
Epidemiology and healthcare utilization of neurogenic bladder patients in a us claims database | Q46560975 | ||
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity | Q46586297 | ||
European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity | Q47892069 | ||
Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life | Q47966680 | ||
Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity | Q48389748 | ||
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial | Q48621733 | ||
Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. | Q49073287 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P921 | main subject | botulinum toxin type A | Q4095199 |
P304 | page(s) | 53-61 | |
P577 | publication date | 2017-03-24 | |
P1433 | published in | International neurourology journal | Q26842093 |
P1476 | title | Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis | |
P478 | volume | 21 |
Q91768465 | Guideline for the management of pre-, intra-, and postpartum care of women with a spinal cord injury | cites work | P2860 |
Search more.